Ethicon is at the forefront of advancing surgical care to help patients with obesity live longer and better.

Each piece of evidence moves bariatric surgery forward to support optimal patient care through safety, effectiveness and access.

Major areas of research and evidence:

**Obesity-related disease state research**
- Mechanisms of action
- Glycemic control in type 2 diabetes
- Complications with diabetes
- Cardiovascular disease
- Osteoarthritis

**Health economics of obesity and bariatric surgery**
- Burden of obesity and obesity-related disease
- Cost-effectiveness of bariatric surgery
- Characterization of surgically open patients within bariatric surgery eligible populations

**Products to improve outcomes in bariatric surgery**
- Biosurgery
- Energy
- Staplers
- Wound closure

**Emerging bariatric and metabolic procedures**
- Sleeve gastrectomy
- Partial jejunal diversion
- Duodenal switch

Safety + Effectiveness + Access = Optimal patient care
Big ideas start small: How evidence evolves and change takes shape

Ethicon is committed to evidence, because we are focused on improving patient care and outcomes.

Ethicon begins funding groundbreaking MARS preclinical study program (ongoing) to understand metabolic mechanisms of bariatric surgery. Ethicon funds real-world evidence. This is one of the first studies to demonstrate survival and economic benefits of gastric bypass. Ethicon funds first meta-analysis of bariatric surgical literature to understand reproducibility and outcomes of similar bariatric procedures around the world. Ethicon funds U.S. RWE study demonstrating cost-effectiveness of bariatric surgery.

Ethicon partners with societies and surgeons to gain coverage for bariatric surgery. Ethicon partners with societies and surgeons to gain coverage for bariatric surgery. Ethicon publishes proof of concept, feasibility study of partial jejunal diversion, a novel, anatomy sparing procedure developed out of the Ethicon MARS program.

Ethicon publishes RWE showing benefits with ECHelon FLEX™ Powered Staplers. This evidence included benefits in hemorrhage-related complications; cost-savings of powered stapling in bariatric surgery, and preclinical evidence on mucosal capture and its impact on staple line leaks.

STAMPEDE published for third time in the NEJM® and cited in global clinical guidelines from international diabetes organizations, that for the first time includes bariatric surgery as treatment option for diabetes.

Ethicon funds studies to characterize the surgically open (and eligible) population and patient engagement in the obesity care path, the progression of obesity, and the impact of incidence of co-morbidities.


RWE = real-world evidence
RCT = randomized controlled trial

The third-party trademarks used herein are trademarks of their respective owners. ©2017 Ethicon, Inc. All rights reserved. 078677-170815